Goldman Sachs hosted a gathering with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (efficient January 1, 2025).
The analyst maintains the Purchase ranking with a worth goal of $33.
When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift towards prioritizing efforts. The main target can be on alternatives anticipated to ship the very best financial returns whereas sustaining a balanced portfolio of high-risk and low-risk initiatives.
With an annual R&D funds of about $11-12 billion—representing roughly a high-teens share of income—the corporate plans to allocate assets to key areas resembling Oncology and reaffirmed its dedication to packages concentrating on weight problems, cardiovascular, and metabolic illnesses.
Additionally Learn: European And US Vaccine Shares Are Underneath Strain – Right here’s Why
The analyst notes that Boshoff believes the anti-obesity drugs market remains to be in its early phases. He envisions a future during which the market is segmented primarily based on elements like co-morbidities, completely different remedy mechanisms, supply strategies (Pfizer focuses on oral supply), and mixture therapies enjoying essential roles.
Boshoff informed the analyst that anti-obesity medicines are anticipated to change into extra built-in into main care. He highlighted Pfizer’s robust historical past with extensively used drugs like Lipitor and Eliquis, suggesting this expertise aligns with their strategic targets.
Amongst Pfizer’s three clinical-stage anti-obesity packages, Boshoff expressed confidence in a single molecule doubtlessly being among the many first oral GLP-1/AOMs accessible within the U.S. market.
Goldman Sachs provides that Pfizer sees Comirnaty and Paxlovid as dependable long-term merchandise. The corporate expects regular demand on account of ongoing COVID-19 mutations. The corporate anticipates extra secure vaccination charges and improved business stability total.
Within the third quarter, the U.S. drugmaker reported gross sales of $17.70 billion, up 31% year-over-year (up 32% operationally), beating the consensus of $14.95 billion.
The rise was primarily led by progress contributions from Paxlovid and a number of other acquired merchandise, key in-line merchandise, and current business launches.
Concerning its COVID-19 and influenza mixture vaccine, Pfizer stays optimistic about its market potential and is testing new formulations to beat challenges from earlier scientific knowledge.
Pfizer acknowledges setbacks in its immunology pipeline however stays dedicated and plans to deal with advancing choose early-stage pipeline initiatives.
Worth Motion: PFE inventory is down 0.77% at $25.62 eventually verify Tuesday.
Goldman Sachs hosted a gathering with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (efficient January 1, 2025).
The analyst maintains the Purchase ranking with a worth goal of $33.
When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift towards prioritizing efforts. The main target can be on alternatives anticipated to ship the very best financial returns whereas sustaining a balanced portfolio of high-risk and low-risk initiatives.
With an annual R&D funds of about $11-12 billion—representing roughly a high-teens share of income—the corporate plans to allocate assets to key areas resembling Oncology and reaffirmed its dedication to packages concentrating on weight problems, cardiovascular, and metabolic illnesses.
Additionally Learn: European And US Vaccine Shares Are Underneath Strain – Right here’s Why
The analyst notes that Boshoff believes the anti-obesity drugs market remains to be in its early phases. He envisions a future during which the market is segmented primarily based on elements like co-morbidities, completely different remedy mechanisms, supply strategies (Pfizer focuses on oral supply), and mixture therapies enjoying essential roles.
Boshoff informed the analyst that anti-obesity medicines are anticipated to change into extra built-in into main care. He highlighted Pfizer’s robust historical past with extensively used drugs like Lipitor and Eliquis, suggesting this expertise aligns with their strategic targets.
Amongst Pfizer’s three clinical-stage anti-obesity packages, Boshoff expressed confidence in a single molecule doubtlessly being among the many first oral GLP-1/AOMs accessible within the U.S. market.
Goldman Sachs provides that Pfizer sees Comirnaty and Paxlovid as dependable long-term merchandise. The corporate expects regular demand on account of ongoing COVID-19 mutations. The corporate anticipates extra secure vaccination charges and improved business stability total.
Within the third quarter, the U.S. drugmaker reported gross sales of $17.70 billion, up 31% year-over-year (up 32% operationally), beating the consensus of $14.95 billion.
The rise was primarily led by progress contributions from Paxlovid and a number of other acquired merchandise, key in-line merchandise, and current business launches.
Concerning its COVID-19 and influenza mixture vaccine, Pfizer stays optimistic about its market potential and is testing new formulations to beat challenges from earlier scientific knowledge.
Pfizer acknowledges setbacks in its immunology pipeline however stays dedicated and plans to deal with advancing choose early-stage pipeline initiatives.
Worth Motion: PFE inventory is down 0.77% at $25.62 eventually verify Tuesday.
